Quetiapine Immediate Release — Competitive Intelligence Brief

Quetiapine Immediate Release (Quetiapine Immediate Release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic. Area: Psychiatry.

marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry Small molecule

Target snapshot

Quetiapine Immediate Release (Quetiapine Immediate Release) — AstraZeneca. Quetiapine blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Quetiapine Immediate Release TARGET	Quetiapine Immediate Release	AstraZeneca	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone, Haloperidol	Risperidone, Haloperidol	Ludwig-Maximilians - University of Munich	marketed	Antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperdal Consta	Risperdal Consta	Zogenix, Inc.	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
paliperidone clozapine	paliperidone clozapine	Universidad Nacional de Rosario	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Oral Olanzapine	Oral Olanzapine	Eli Lilly and Company	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor
Risperidone Long Acting	Risperidone Long Acting	Dartmouth-Hitchcock Medical Center	marketed	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT2A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic class)

1. Shanghai Mental Health Center · 10 drugs in this class
2. AstraZeneca · 6 drugs in this class
3. Otsuka Pharmaceutical Development & Commercialization, Inc. · 5 drugs in this class
4. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 4 drugs in this class
5. Eli Lilly and Company · 4 drugs in this class
6. Otsuka Pharmaceutical Co., Ltd. · 3 drugs in this class
7. Medical University of Vienna · 2 drugs in this class
8. Organon and Co · 2 drugs in this class
9. Chengdu Kanghong Pharmaceutical Group Co., Ltd. · 2 drugs in this class
10. H. Lundbeck A/S · 2 drugs in this class